Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia

Area of Science:

• Cardiology
• Pharmacology
• Biotechnology

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic heart disease, and stroke.
• Statins are primary treatments for hyperlipidemia but often insufficient for patients with genetic predispositions or established ASCVD.
• Suboptimal lipid management contributes to persistent cardiovascular event risk.

Purpose of the Study:

• To evaluate the efficacy and safety of inclisiran, a novel siRNA-based therapy, for managing LDL-C in specific patient populations.
• To assess inclisiran's role as an adjunct therapy for patients with heterozygous familial hypercholesterolemia or clinical ASCVD on maximally tolerated statins.
• To determine if inclisiran can help patients achieve target LDL-C levels when statins alone are inadequate.

Main Methods:

• Inclisiran administration as a twice-yearly subcutaneous injection.
• Clinical trials assessing LDL-C reduction in patients with heterozygous familial hypercholesterolemia and clinical ASCVD.
• Evaluation of safety and tolerability profiles in conjunction with maximally tolerated statin therapy.

Main Results:

• Inclisiran demonstrated significant and robust reduction in LDL-C levels across clinical trials.
• The injectable therapy was associated with a favorable safety and tolerability profile.
• Patients achieved target LDL-C levels more effectively when inclisiran was added to statin therapy.

Conclusions:

• Inclisiran represents a significant advancement in lipid-lowering therapy, offering a convenient, infrequent dosing regimen.
• This novel agent is effective in reducing LDL-C in high-risk patients, including those with familial hypercholesterolemia and established ASCVD.
• Further research is ongoing to ascertain the long-term impact of inclisiran on major adverse cardiovascular events.